CRX.L Regulatory News (CRX)

Press release

Cyprotex PLC

("Cyprotex" or the "Company" or the "Group")

AGM Statement

30 June 2011 - Cyprotex PLC (AIM: CRX), the preclinical ADME-Tox services company, will hold its Annual General meeting today. At that meeting, Steve Harris, Chairman, will make the following comments:

'2010 was a transformational year for Cyprotex. The Company successfully executed a major acquisition of a fast-growing competitor, entered the nascent in vitro toxicology market, completed a major expansion of its Macclesfield laboratories, doubled its core service offerings, and more than doubled its rate of new-customer acquisition.

'Revenues from continuing operations were up 7.5%. Despite heavy investment in expanding operations and its service portfolio, the Company continued to be profitable.

'The integration of Apredica and Cyprotex has gone well. Revenues from our 2010 acquisition have so far exceeded our original expectations. With the integration efforts behind us, the Company is now again searching for complementary acquisition targets.

'The Company's successes have been achieved in the face of an unfavourable economic climate for the drug-discovery industry. Established pharmaceutical companies have been substantially reducing their R&D efforts. Emerging companies have experienced severe difficulties in obtaining funding. These difficulties, however, are making Cyprotex's ability to improve the efficiency of drug development ever more appealing.'

Cyprotex expects to announce its interim results for the six months to 30 June 2011 on 25 August 2011.

For further information:

Notes to Editors:

Cyprotex PLC

Cyprotex is the world's largest contract research organisation (CRO) specialising in ADME Tox, which is the analysis of the Absorption, Distribution, Metabolism, Excretion, and Toxicity properties of potential drugs, cosmetics, and agrochemicals. It is the only company in the world with in-house capabilities for both in vitro (test tube) and in silico (computer modelling) ADME Tox. Cyprotex was founded in 1999 and listed on the AIM in 2002. It has laboratories in Macclesfield, Cheshire, UK (near Manchester), and Watertown, Massachusetts, USA (near Boston), making it one of only three ADME Tox CROs with international operations.